ZeroStack Corp. held its 2026 Annual Meeting where shareholders approved all proposals, including the election of five directors, reappointment of auditors, and amendments to its incentive plan. The company also ratified a private cryptocurrency financing, enabling it to acquire shares and tokens through its subsidiary Texas Blocker Corp. Additionally, ZeroStack's subsidiary Phatebo GmbH secured $14.7 million in pharmaceutical purchase orders but needs non-dilutive financing to fulfill them. The approvals and financing efforts position ZeroStack to expand its AI-focused asset management and pharmaceutical distribution businesses.
The Rosen Law Firm is investigating potential securities claims against Hyliion Holdings Corp. following allegations that the company misled investors with materially false business information. This comes after a short-seller report questioned the l...
Morgan Stanley's spot Bitcoin ETF increased its holdings by about 232.5 BTC, valued at $15.05 million, raising total assets to over 6,500 BTC worth more than $426 million. This accumulation occurred as Bitcoin traded below $65,000, a level below the ...
Altria remains a strong buy with a 6.3% dividend yield and a 60-year streak of dividend increases, with another hike expected on August 27. Despite challenges like declining cigarette volumes and regulatory risks, Altria sustains dividend growth thro...
Matthews International has lowered its EBITDA guidance for fiscal 2026 by 10%, now expecting $158–$162 million due to restructuring costs and delayed benefits from its Propelis segment. The industrial tech division faces ongoing legal disputes, press...
Intuitive Surgical's stock is down 34% year-to-date, trading at $373.71 versus an average Wall Street target of $477.25, reflecting a 28% discount. The decline followed slower-than-expected growth guidance and tariff pressures, but the company contin...
